Select Page
Panel Discussion - ViroChannel

ViroChannel brings together healthcare professionals, with a focus in virology, to learn from guest experts and discuss the most relevant clinical practice challenges facing them today.

HIV-Associated Enteropathy

with Drs. Calvin Cohen, David Michael Asmuth, Gary Blick, Mark A. Wainberg,  and Michael S. McGrath

THE PANEL

HIV-Associated Enteropathy

SUMMARY

In this program Dr. Calvin Cohen at CROI 2014 interviews a panel of experts on the management of HIV-associated enteropathy.

The panel summarizes key data findings at CROI 2014 surrounding HIV-associated enteropathy, discusses the effect HIV has on the enteric mucosa, the challenges in diagnosis and management, as well as emerging treatments.

The panel further points out the consequences of such a chronic inflammation response and the importance of early detection and treatment.

This activity is supported by
an educational grant from:

Entera Health

KEY LEARNING POINTS

Upon completion of this activity, participants should be better able to:

  • Identify the current features of the clinical presentation of HIV-associated enteropathy including the initiation of the etiology and what biomarkers should be added to determine impact of HIV disease progression besides viral load and CD4 counts
  • Define the implications of HIV-associated enteropathy and immune reconstitution
  • Explain how microbial translocation and the associated elevation of expression of inflammatory cytokines affect the recombination of Th17s and other important cell factors in the immune system
  • Explain HIV-related microbial translocation contribute to the pathogenesis of systemic viremia and how HIV contributes to gut microbiota evisceration
  • Identify co-morbidities are associated with HIV-associated enteropathy
  • Explain how microbial translocation is associated with increased cardiovascular risk in HIV patients
  • Describe what future trends in research on HIV-associated enteropathy will look like and how the data on EnteraGam is going to predictably influence the treatment of HIV in clinical practice

PARTICIPANTS

Calvin Cohen, MD, MSc

Calvin Cohen, MD, MSc

HOST

Research Director
CRI New England 
Harvard Vanguard
Medical Associates
Harvard Medical School
Boston, Massachusetts, USA

David Michael Asmuth, MD

David Michael Asmuth, MD

Panelist

Professor of Medicine
University of California
Davis Medical Center
Sacramento, California, USA

Gary Blick, MD, AAHIS

Gary Blick, MD, AAHIS

Panelist

President | Founder
World Health Clinicians, Inc.
Circle C.A.R.E. Center
Norwalk, Connecticut, USA

Mark A. Wainberg, PhD

Mark A. Wainberg, PhD

Panelist

Director
McGill AIDS Center
Professor of Medicine
McGill University
Montréal, Québec, Canada

Michael S. McGrath, MD, PhD

Michael S. McGrath, MD, PhD

Panelist

Professor
Laboratory Medicine
Medicine and Pathology
University of California in San Francisco
California, USA

PROGRAM

DISCLOSURE

ViroChannel has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.


Calvin Cohen, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Advisory: Bristol-Myers Squibb, Janssen, Merck, ViiV Healthcare

Consultant: AbbVie

Industry funded research investigator + advisory: Gilead

David Michael Asmuth, MD, has a financial interest/relationship or affiliation in the form of:
Consultant: ViiV Healthcare, Merck, Pfizer, Entera Health

Gary Blick, MD, AAHIS, has a financial interest/relationship or affiliation in the form of:
Industry funded research/investigator: Sangamo Bioscience, Gilead
Speakers Bureau, Faculty, Peer reviewer Advisory Committee/Board: ViiV Healthcare, Janssen, Bristol-Myers Squibb
Industry funded research/investigator: AbbVie

Mark A. Wainberg, PhD, has a financial interest/relationship or affiliation in the form of:
Industry funded research / investigator and Speakers Bureau, Faculty, Peer Reviewer Advisory Committee/Board: ViiV HealthCare
Consultant: Merck, Gilead

Michael S. McGrath, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant, Stock/Ownership, Patent holder: Pathologica
Consultant: Navidea


Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses. No responsibility is taken for errors or omissions. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.